Form 4: Apellis Pharmaceuticals Acquired by Biogen for $41/Share

Director Keli Walbert reports the disposal of all equity holdings in Apellis Pharmaceuticals following the company's acquisition by Biogen.

Summary

• Apellis Pharmaceuticals has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• Shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 upon the achievement of specific milestones.
• All outstanding common stock, restricted stock units (RSUs), and vested stock options held by the reporting person were cancelled and converted into the right to receive the merger consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral-to-positive event for shareholders, as it marks the successful completion of a merger and provides immediate cash liquidity, though it signals the end of the company as an independent entity.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share based on future milestones.
• The transaction successfully closed, providing liquidity to equity holders.

Negatives

• The reporting person no longer holds any equity interest in Apellis Pharmaceuticals as the company is now a wholly-owned subsidiary of Biogen.
• Future upside is limited to the achievement of specific milestones defined in the CVR agreement.

Risks

• The realization of the additional $4.00 per share is contingent upon meeting specific, non-guaranteed milestones.
• The CVRs are non-transferable, limiting liquidity for holders until milestone outcomes are determined.

Future Outlook

The company is now a wholly-owned subsidiary of Biogen, and future performance is subject to the integration and milestone achievements defined in the CVR agreement.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biopharmaceutical sector, with Biogen expanding its portfolio through the acquisition of Apellis, a move consistent with recent trends of large-cap pharma acquiring specialized biotech firms to bolster pipelines.

Comparison to Industry Standards

• The use of CVRs in this acquisition is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding pipeline assets.
• The $41.00 cash offer reflects a premium typical for mid-cap biotech acquisitions in the current regulatory and market environment.

Corporate Governance

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees and operations are now under the governance of Biogen Inc.

Next Steps

• Achievement of milestones related to the CVR agreement.
• Final distribution of CVR payments if milestones are met.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, CVR, Tender Offer